It is worth noting that it is now widely accepted that pyruvate dehydrogenase kinase 3 (PDK3) and histone deacetylase 6 (HDAC6) inhibitors can be used to treat lung cancer [16,17]. This evidence concerns the gene PDK3 and lung carcinoma.